Jianxiang Wang, MD, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, shares key Chinese CAR-T clinical trials to look out for. Two different clinical trials investigating CD19 CAR T-cells for non-Hodgkin lymphoma are almost completed, and approval is expected soon in China. Additionally, clinical trials studying BCMA CAR T-cell therapy for multiple myeloma are also making good progress. Lastly, Prof. Wang highlights clinical trials evaluating CD19 CAR T-cells for relapsed/refractory acute lymphoblastic leukemia (ALL), particularly for adults. This interview took place during the 3rd European CAR T-cell Meeting.